Salarius Pharmaceuticals Presents SP-3164 Preclinical Data
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s
Globe Newswire27-01-2023, 20:39
Curia wins 2023 Frost & Sullivan Customer Value Leadership Award 29-06-2023, 20:00